STAR.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 12:00):

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally...

Stats
Dagens volum	129 542
Gjennomsnittsvolum	525 897
Markedsverdi	80.57B
EPS	INR0 ( 2024-01-29 )
Neste inntjeningsdato	( INR0 ) 2024-05-23
Last Dividend	INR1.500 ( 2023-08-04 )
Next Dividend	INR0 ( N/A )
P/E	-52.09
ATR14	INR1.169 (0.13%)

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: -0.74 (moderate negative)

Signal:(33.632) Neutral

Strides Pharma Science Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Strides Pharma Science Korrelasjon - Valuta/Råvare

-0.47
( neutral )

-0.55
( weak negative )

-0.52
( weak negative )

-0.56
( weak negative )

0.62
( weak )

0.56
( weak )

Strides Pharma Science Økonomi

Annual	2022
Omsetning:	INR36.88B
Bruttogevinst:	INR20.62B (55.89 %)
EPS:	INR-25.63

FY	2022
Omsetning:	INR36.88B
Bruttogevinst:	INR20.62B (55.89 %)
EPS:	INR-25.63

FY	2022
Omsetning:	INR30.22B
Bruttogevinst:	INR14.39B (47.61 %)
EPS:	INR-52.84

FY	2021
Omsetning:	INR32.51B
Bruttogevinst:	INR18.42B (56.67 %)
EPS:	INR29.96

Financial Reports:

No articles found.

Strides Pharma Science Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Strides Pharma Science Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.216 - low (50.00%) | Divividend Growth Potential Score: 1.260 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.500	2010-05-21
Last Dividend	INR1.500	2023-08-04
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR651.50	--
Avg. Dividend % Per Year	0.19%	--
Score	0.96	--
Div. Sustainability Score	0.216
Div.Growth Potential Score	1.260
Div. Directional Score	0.738	--

Next Divdend (Est)
(2024-05-08)

INR0 Estimate 3.16 %

Dividend Stability

0.25 Very Poor

Dividend Score

0.96

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.36%
2019	INR15.00	3.22%
2020	INR2.00	0.55%
2021	INR2.50	0.28%
2022	INR0	0.00%
2023	INR1.500	0.42%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SATIA.NS	Dividend Junior	2023-09-22	Annually	6	0.35%
MAHINDCIE.NS	Dividend Junior	2023-06-02	Annually	3	0.66%
GNA.NS	Dividend Junior	2023-08-31	Annually	7	1.43%
ATFL.NS	Dividend Junior	2023-07-04	Annually	16	0.24%
TNPETRO.NS	Dividend Junior	2023-09-18	Sporadic	23	2.02%
PFIZER.NS	Dividend Junior	2023-08-11	Annually	22	0.82%
JAYBARMARU.NS	Dividend Junior	2023-09-08	Annually	23	1.48%
DCMSHRIRAM.NS	Dividend Junior	2023-07-18	Semi-Annually	23	1.23%
SIYSIL.NS	Dividend Junior	2023-07-24	Semi-Annually	18	1.37%
MEDICAMEQ.NS	Ex Dividend Junior	2023-09-20	Annually	3	0.02%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0259	1.500	-0.519	-0.778	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0487	1.500	-1.652	-2.48	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.132	1.000	-0.692	-0.692	[3 - 30]
operatingCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.589	1.000	3.52	3.52	[0.2 - 0.8]
operatingProfitMarginTTM	0.0901	1.000	-0.198	-0.198	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				0.216

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-78.46	1.000	-8.03	0	[1 - 100]
returnOnEquityTTM	-0.0487	2.50	-1.062	-2.48	[0.1 - 1.5]
freeCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.170	1.500	5.74	0	[0 - 0.4]
operatingCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0868	1.000	-0.330	0	[0.1 - 0.5]
Total Score				1.260

Strides Pharma Science

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.